Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.
The in vitro activity of the new penem derivative ALP-201 against 226 aerobic and 350 anaerobic clinical bacterial isolates was determined using agar dilution techniques. For comparison amoxicillin, cefaclor, ceftazidime, doxycycline, erythromycin, imipenem and trimethoprim/sulfamethoxazole were also tested with aerobic bacteria, and cefoxitin, chloramphenicol, clindamycin, imipenem, metronidazole and piperacillin with anaerobic bacteria. ALP-201 was found to be highly active against Escherichia coli, Klebsiella spp., Enterobacter spp., Haemophilus influenzae, Branhamella catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, anaerobic cocci, Propioni-bacterium acnes, Clostridium perfringens, Bacteroides fragilis, Bacteroides spp. and fusobacteria. Pseudomonas aeruginosa and Clostridium difficile were resistant to ALP-201. When tested against aerobic bacteria using a high inoculum or using the broth dilution technique, the activity of ALP-201 showed little dependence on inoculum size and the bactericidal activity was similar to the inhibitory activity. Further investigations are warranted with ALP-201, which is absorbed from the gastrointestinal tract after oral administration.
Rylander
M
M
Department of Clinical Microbiology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
Nord
C E
CE
Norrby
S R
SR
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001420:Bacteria, Aerobic / Q000187:drug effects* / Q000302:isolation & purification; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy; D015780:Carbapenems / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D015780:Carbapenems; C060114:SUN 5555